Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273112 | 0.99 | LMNA (0.45) | LMNATHRBTDP1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL5710125 | 0.89 | TDP1 (0.43) | LMNATHRBTDP1MAPTKDM4E | |
| SCHEMBL27919377 | 0.88 | TDP1 (0.44) | LMNATHRBTDP1MAPTKDM4E | |
| SCHEMBL2476369 | 0.86 | TDP1 (0.38) | LMNATHRBTDP1MAPTALDH1A1 | |
| SCHEMBL16063623 | 0.84 | LMNA (0.45) | LMNATHRBMAPTKDM4EALDH1A1 | |
| SCHEMBL7653910 | 0.84 | TDP1 (0.38) | LMNATHRBTDP1MAPTKDM4E | |
| SCHEMBL2476365 | 0.83 | TDP1 (0.40) | LMNATHRBTDP1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL4432331 | 0.82 | MAPT (0.49) | LMNATDP1MAPTKDM4EALDH1A1 | |
| SCHEMBL2720971 | 0.81 | TDP1 (0.47) | LMNATDP1MAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5710126 | 0.80 | PPID (0.41) | LMNAMAPTKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103254197-A | Preparation method of anagrelide hydrochloride | UNIV HEILONGJIANG | 2013-08-21 | — | — | CN | disclosed |
| US-8133996-B2 | Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride | CIPLA LIMITED (IN) | 2012-03-13 | — | — | US | disclosed |
| US-8133996-B2 | Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride | CIPLA LIMITED (IN) | 2012-03-13 | — | — | US | disclosed |
| US-20100305318-A1 | Process for the Manufacture of Anagrelide Hydrochloride Monohydrate | Watson Pharma Private Limited (IN) | 2010-12-02 | — | — | US | disclosed |
| EP-2222375-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF ANAGRELIDE HIDROCHLORIDE MONHYDRATE | Watson Pharma Private Limited (IN) | 2010-09-01 | — | — | EP | disclosed |
| US-20100075999-A1 | Process for the Preparation of Ethyl-N-(2,3-Dichloro-6-Nitrobenzyl)Glycine Hydrochloride | CIPLA LIMITED (IN) | 2010-03-25 | — | — | US | disclosed |
| US-20100075999-A1 | Process for the Preparation of Ethyl-N-(2,3-Dichloro-6-Nitrobenzyl)Glycine Hydrochloride | CIPLA LIMITED (IN) | 2010-03-25 | — | — | US | disclosed |
| EP-2114856-A1 | PROCESS FOR THE PREPARATION OF ETHYL-N-(2, 3-DICHLORO-6-NITROBENZYL) GLYCINE HYDROCHLORIDE | Cipla Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009087673-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF ANAGRELIDE HIDROCHLORIDE MONHYDRATE | Watson Pharma Private Limited (IN) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008096145-A1 | PROCESS FOR THE PREPARATION OF ETHYL-N-(2, 3-DICHLORO-6-NITROBENZYL) GLYCINE HYDROCHLORIDE | CIPLA LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
| EP-1700842-A2 | Method for the Manufacture of Anagrelide | Shire US Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060148832-A1 | Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents | CHEMISCH-PHARMAZEU TISCHES LABOR ROLF SACHSE GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1581506-A1 | USE OF 2-AMINO-2H-QUINAZOLINE DERIVATIVES FOR PRODUCING THERAPEUTIC AGENTS | Chemisch-Pharmazeutisches Labor Rolf Sachse GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063172-A1 | USE OF 2-AMINO-2H-QUINAZOLINE DERIVATIVES FOR PRODUCING THERAPEUTIC AGENTS | CHEMISCH-PHARMAZEU TISCHES LABOR ROLF SACHSE GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1373268-A2 | METHOD FOR THE MANUFACTURE OF ANAGRELIDE | Shire US Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6653500-B2 | Making ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde, reducing the glycine compound using tin dichloride or a catalyst and cyclization of the corresponding iminoquinazoline compound | SHIRE US INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SHIRE US INC. | 2003-03-27 | — | — | US | disclosed |
| US-6388073-B1 | NITRATION A 3,4-DICHLOROBENZALDEHYDE; REDUCING; CHLORINATION; ALKYLATION; BROMOCYANATION; CHLIZATION | SHIRE US INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2002008228-A2 | METHOD FOR THE MANUFACTURE OF ANAGRELIDE | SHIRE US INC (US) | 2002-01-31 | — | — | WO | disclosed |
| US-4146718-A | BLOOD PLATELET ANTIAGGREGATIVE AGENT | BRISTOL-MYERS COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148832-A1 | Use of 2-amino-2h-quinazoline derivatives for producing therapeutic agents | ABL1, JAK2, HRH2 | GAA 4085/4885LMNA 4371/4885THRB 3048/4885 |
| US-20100305318-A1 | Process for the Manufacture of Anagrelide Hydrochloride Monohydrate | GCGR, MPL, UGT1A9 | GAA 568/4885LMNA 3728/4885THRB 4131/4885 |
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SUCLG2, PDCD2L, ICOSLG | GAA 313/4885LMNA 2498/4885THRB 4635/4885 |
| US-20100075999-A1 | Process for the Preparation of Ethyl-N-(2,3-Dichloro-6-Nitrobenzyl)Glycine Hydrochloride | CDK13, CBR3, SUCNR1 | GAA 3710/4885LMNA 3964/4885THRB 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.